{"SPADE_UN_12139": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_12139", "Peptide Name": "WW (De Novo Synthesis)", "Source": "synthetic construct", "Family": "Not found", "Gene": "Not found", "Sequence": "WWKAAAKAAAKWW", "Sequence Length": 13, "UniProt Entry": "No entry found", "Protein Existence": "Synthetic form", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-"], "Target Organism": "[Ref.30897850] Gram-positive bacteria:Staphylococcus aureus ATCC 27853(MIC=4μM), Staphylococcus epidermidis ATCC 12228(MIC=4μM), Staphylococcus faecalis ATCC 29212(MIC=4μM), Bacillus subtilis CMCC 63501(MIC=4μM);Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC=2μM), Escherichia coli UB 1005 (MIC=4μM), Pseudomonas aeruginosa ATCC 27853(MIC=8μM), Salmonella typhimurium ATCC 14028(MIC=8μM)", "Hemolytic Activity": "[Ref.30897850] 24% hemolysis at 256μM against human red blood cells", "Cytotoxicity": "[Ref.30897850] ①The cell viability of RAW 264.7 induced by WW is 104.3%, 103.6%, 109.4%, 103.6%, 97.5%, 89.9%, 63.4% at peptide concentrations of 1, 2, 4, 8, 16, 32, 64 μM, while the cytotoxicity of WV on RAW 264.7 cells (Control samples) is 93.1%, 67.8%, 37.7%, 17.8%, 0%, 1.4% and 1.1% at peptide concentrations of 1, 2, 4, 8, 16, 32, 64 μM.②The cell viability of HEK293T induced by WV is 102.9%, 111.6%, 105.1%, 104.3%, 101.8%, 84.8%, 43.5% at peptide concentrations of 1, 2, 4, 8, 16, 32, 64 μM, while the cytotoxicity of WV on HEK293T cells (Control samples) is 101.4%, 80.1%, 31.9%, 1.4%, 1.4%, 1.8% and 1.1% at peptide concentrations of 1, 2, 4, 8, 16, 32, 64 μM.", "Binding Target": "Not found", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Amidaton", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C80H108N20O14", "Mass": 1573.84, "PI": 10.3, "Net Charge": 3, "Hydrophobicity": -0.35, "Half Life": "Mammalian:2.8 hourYeast:3 minE.coli:2 min", "Function": "Antibacterial activity against Gram-positive bacteria and Gram-nagetive bacteria.", "Literature": [{"Title": "Symmetrical Modification of Minimized Dermaseptins to Extend the Spectrum of Antimicrobials with Endotoxin Neutralization Potency", "Pubmed ID": "30897850", "Reference": "Int J Mol Sci. 2019 Mar; 20(6) 1417. Published online 2019 Mar 20. doi 10.3390/ijms20061417", "Author": "Changxuan Shao, Weizhong Li, Peng Tan, Anshan Shan, Xiujing Dou, Deying Ma, Chunyu Liu", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30897850"}], "Frequent Amino Acids": "AWK", "Absent Amino Acids": "CDEFGHILMNOPQRSTUVY", "Basic Residues": 3, "Acidic Residues": 0, "Hydrophobic Residues": 10, "Polar Residues": 9, "Positive Residues": 3, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_03541", "Similarity": 1.0, "Sequence": "FPVTWRWWKWWKG"}, {"SPADE_ID": "SPADE_N_03548", "Similarity": 1.0, "Sequence": "FSVTWRWWKWWKG"}, {"SPADE_ID": "SPADE_N_03549", "Similarity": 1.0, "Sequence": "FPVTWGWWKWWKG"}]}}}